← Back to Search

Virus Therapy

Bacteriophage Therapy for Urinary Tract Infection

Phase 1 & 2

Waitlist Available

Led By Robert J Hopkins, MD

Research Sponsored by Adaptive Phage Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial is testing whether a new therapy, using viruses to kill bacteria, can treat urinary tract infections.

Eligible Conditions

Urinary Tract Infection (UTI)

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Identify ideal bacteriophage treatment regimens based on improvements in disease control rates

Secondary outcome measures

Phage Therapy

Assess the tolerability of bacteriophage therapy

Other outcome measures

Recurrence of urinary tract infection

Trial Design

6Treatment groups

Experimental Treatment

Group I: Subcohort DExperimental Treatment1 Intervention

Selected phage for Klebsiella pneumoniae administered via selected route based on previous arms.

Group II: Subcohort CExperimental Treatment1 Intervention

Selected phage for E. coli administered via selected route based on previous Arms.

Group III: Subcohort BExperimental Treatment1 Intervention

Selected phage for Klebsiella pneumoniae administered via selected route based on previous Arms.

Group IV: Subcohort AExperimental Treatment1 Intervention

Selected phage for E. coli administered via selected route based on previous Arms.

Group V: Intravesical (IVS)Experimental Treatment1 Intervention

Phage administered via the intravesical route.

Group VI: Intravenous (IV)Experimental Treatment1 Intervention

Phage administered via the intravenous route.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Adaptive Phage Therapeutics, Inc.Lead Sponsor

5 Previous Clinical Trials

126 Total Patients Enrolled

United States Department of DefenseFED

864 Previous Clinical Trials

327,598 Total Patients Enrolled

1 Trials studying Urinary Tract Infection

2 Patients Enrolled for Urinary Tract Infection

Robert J Hopkins, MDPrincipal InvestigatorChief Medical Officer

1 Previous Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In how many diverse locations is this experiment being conducted?

"There are a total of 8 research facilities currently running this clinical trial. Some notable locations include AMPM Research Clinic in Miami Gardens, AdMed Research in Miami, and University of Texas Southwestern Medical Center in Dallas."

Answered by AI

Can people with the specified medical condition join this trial right now?

"The clinical trial in question is not currently looking for new participants. It was first posted on December 9th, 2020 and has since been updated on October 25th, 2022. There are 850 other trials that are still recruiting patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Bacteriophage Therapy in Patients With Urinary Tract Infections

2020. "Bacteriophage Therapy in Patients With Urinary Tract Infections". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04287478.